149 related articles for article (PubMed ID: 37774670)
1. Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease.
Kim DH; Lee KJ; Park J; Chi S; Han J; Bang Y; Kim SM; Kang SG; Cha SH; Han YH
Biomed Pharmacother; 2023 Nov; 167():115587. PubMed ID: 37774670
[TBL] [Abstract][Full Text] [Related]
2. Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the
Alsuraih M; O'Hara SP; Woodrum JE; Pirius NE; LaRusso NF
JHEP Rep; 2021 Jun; 3(3):100250. PubMed ID: 33870156
[TBL] [Abstract][Full Text] [Related]
3. Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation.
Jang YS; Lee K; Park M; Joo Park J; Choi GM; Kim C; Dehkohneh SB; Chi S; Han J; Song MY; Han YH; Cha SH; Goo Kang S
Cytokine; 2023 Dec; 172():156413. PubMed ID: 37918054
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis.
Cazzagon N; Sarcognato S; Floreani A; Corrà G; De Martin S; Guzzardo V; Russo FP; Guido M
JHEP Rep; 2021 Jun; 3(3):100286. PubMed ID: 34041468
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.
Elßner C; Goeppert B; Longerich T; Scherr AL; Stindt J; Nanduri LK; Rupp C; Kather JN; Schmitt N; Kautz N; Breuhahn K; Ismail L; Heide D; Hetzer J; García-Beccaria M; Hövelmeyer N; Waisman A; Urbanik T; Mueller S; Gdynia G; Banales JM; Roessler S; Schirmacher P; Jäger D; Schölch S; Keitel V; Heikenwalder M; Schulze-Bergkamen H; Köhler BC
Gastroenterology; 2019 Mar; 156(4):1190-1205.e14. PubMed ID: 30445013
[TBL] [Abstract][Full Text] [Related]
7. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
Andrews TS; Nakib D; Perciani CT; Ma XZ; Liu L; Winter E; Camat D; Chung SW; Lumanto P; Manuel J; Mangroo S; Hansen B; Arpinder B; Thoeni C; Sayed B; Feld J; Gehring A; Gulamhusein A; Hirschfield GM; Ricciuto A; Bader GD; McGilvray ID; MacParland S
J Hepatol; 2024 May; 80(5):730-743. PubMed ID: 38199298
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
[TBL] [Abstract][Full Text] [Related]
9. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.
Tabibian JH; O'Hara SP; Splinter PL; Trussoni CE; LaRusso NF
Hepatology; 2014 Jun; 59(6):2263-75. PubMed ID: 24390753
[TBL] [Abstract][Full Text] [Related]
11. CsHscB Derived from a Liver Fluke
Yu Q; Koda S; Xu N; Li J; Wang JL; Liu M; Liu JX; Zhang Y; Yang HM; Zhang BB; Li XY; Li XC; Tang RX; Zheng KY; Yan C
Curr Mol Med; 2024; 24(4):505-515. PubMed ID: 37076961
[TBL] [Abstract][Full Text] [Related]
12. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
13. Liver-specific deletion of microRNA-34a alleviates ductular reaction and liver fibrosis during experimental cholestasis.
Wan Y; Zhou T; Slevin E; Koyama S; Li X; Harrison K; Li T; Zhou B; Lorenzo SR; Zhang Y; Xu W; Klaunig JE; Wu C; Shetty AK; Huang CK; Meng F
FASEB J; 2023 Feb; 37(2):e22731. PubMed ID: 36583714
[TBL] [Abstract][Full Text] [Related]
14. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
15. Beta-lapachone ameliorates the progression of primary sclerosing cholangitis pathogenesis in rodent models.
Woo SH; Lee SH; Moon SJ; Han J; Seo KS; Lee H; Lee CH; Hwang JH
Life Sci; 2024 Jan; 337():122342. PubMed ID: 38092141
[TBL] [Abstract][Full Text] [Related]
16. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
17. Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis.
Carpino G; Cardinale V; Renzi A; Hov JR; Berloco PB; Rossi M; Karlsen TH; Alvaro D; Gaudio E
J Hepatol; 2015 Nov; 63(5):1220-8. PubMed ID: 26119688
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis.
Chen YY; Arndtz K; Webb G; Corrigan M; Akiror S; Liaskou E; Woodward P; Adams DH; Weston CJ; Hirschfield GM
JHEP Rep; 2019 Nov; 1(5):369-376. PubMed ID: 32039388
[TBL] [Abstract][Full Text] [Related]
19. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
[TBL] [Abstract][Full Text] [Related]
20. Effects of Melittin Treatment in Cholangitis and Biliary Fibrosis in a Model of Xenobiotic-Induced Cholestasis in Mice.
Kim KH; Sung HJ; Lee WR; An HJ; Kim JY; Pak SC; Han SM; Park KK
Toxins (Basel); 2015 Aug; 7(9):3372-87. PubMed ID: 26308055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
